Structure Therapeutics posts -$106.2M net loss (-72%) as Phase 3 obesity trials launch

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~2 min read

Key Changes

• high

  Net loss widened 72% to $106.2M (diluted EPS -$0.49, down 36%) for Q2 2026 as R&D spending nearly doubled to support Phase 3 ACCOMPLISH program enrolling up to 4,700 patients for aleniglipron in obesity and type 2 diabetes.

  MD&A: Financial Results & Phase 3 Initiation verify on EDGAR →
• high

  Phase 2 ACCESS trials demonstrated placebo-adjusted weight loss up to 16.3% at 44 weeks with favorable discontinuation rates, supporting FDA end-of-Phase-2 guidance and the decision to advance into pivotal registrational studies.

  MD&A: Clinical Data Readouts verify on EDGAR →
• high

  Cash runway extended to end-2028 (from 'at least 2027') on $1.34B balance, funded by $701.5M December 2025 follow-on offering and $100M Genentech licensing fee for non-aleniglipron oral GLP-1 patents; runway now covers Phase 3 registrational costs but excludes pre-commercialization manufacturing.

  MD&A: Liquidity & Capital Resources verify on EDGAR →